🚀 VC round data is live in beta, check it out!
Boule Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Boule Diagnostics and similar public comparables like Clinical Laserthermia, Observe Medical, Advanced Medical, ViroGates and more.
Boule Diagnostics Overview
About Boule Diagnostics
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The firm focuses on the decentralized market segment. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. Through its subsidiaries, the Group operates in Sweden, USA, and China.
Founded
1996
HQ
Employees
212
Website
Sectors
Financials (LTM)
EV
$38M
Boule Diagnostics Financials
Boule Diagnostics reported last 12-month revenue of $55M and EBITDA of $6M.
In the same LTM period, Boule Diagnostics generated $6M in EBITDA and $734K in net income.
Revenue (LTM)
Boule Diagnostics P&L
In the most recent fiscal year, Boule Diagnostics reported revenue of $55M and EBITDA of $5M.
Boule Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $55M | XXX | $55M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $23M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $6M | XXX | $5M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $734K | XXX | ($410K) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (1%) | XXX | XXX | XXX |
| Net Debt | — | — | $18M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Boule Diagnostics Stock Performance
Boule Diagnostics has current market cap of $16M, and enterprise value of $38M.
Market Cap Evolution
Boule Diagnostics' stock price is $0.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38M | $16M | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoule Diagnostics Valuation Multiples
Boule Diagnostics trades at 0.7x EV/Revenue multiple, and 6.8x EV/EBITDA.
EV / Revenue (LTM)
Boule Diagnostics Financial Valuation Multiples
As of April 20, 2026, Boule Diagnostics has market cap of $16M and EV of $38M.
Equity research analysts estimate Boule Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boule Diagnostics has a P/E ratio of 22.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBIT | 7.1x | XXX | 7.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.6x | XXX | XXX | XXX |
| P/E | 22.0x | XXX | (39.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (85.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Boule Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Boule Diagnostics Margins & Growth Rates
Boule Diagnostics' revenue in the last 12 month grew by 1%.
Boule Diagnostics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Boule Diagnostics' rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boule Diagnostics' rule of X is 20% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Boule Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | 57% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Boule Diagnostics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Boule Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinical Laserthermia | XXX | XXX | XXX | XXX | XXX | XXX |
| Observe Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Advanced Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| ViroGates | XXX | XXX | XXX | XXX | XXX | XXX |
| Labo Euromedis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boule Diagnostics M&A Activity
Boule Diagnostics acquired XXX companies to date.
Last acquisition by Boule Diagnostics was on XXXXXXXX, XXXXX. Boule Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Boule Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBoule Diagnostics Investment Activity
Boule Diagnostics invested in XXX companies to date.
Boule Diagnostics made its latest investment on XXXXXXXX, XXXXX. Boule Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Boule Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Boule Diagnostics
| When was Boule Diagnostics founded? | Boule Diagnostics was founded in 1996. |
| Where is Boule Diagnostics headquartered? | Boule Diagnostics is headquartered in Sweden. |
| How many employees does Boule Diagnostics have? | As of today, Boule Diagnostics has over 212 employees. |
| Who is the CEO of Boule Diagnostics? | Boule Diagnostics' CEO is Torben Nielsen. |
| Is Boule Diagnostics publicly listed? | Yes, Boule Diagnostics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Boule Diagnostics? | Boule Diagnostics trades under BOUL ticker. |
| When did Boule Diagnostics go public? | Boule Diagnostics went public in 2011. |
| Who are competitors of Boule Diagnostics? | Boule Diagnostics main competitors are Clinical Laserthermia, Observe Medical, Advanced Medical, ViroGates. |
| What is the current market cap of Boule Diagnostics? | Boule Diagnostics' current market cap is $16M. |
| What is the current revenue of Boule Diagnostics? | Boule Diagnostics' last 12 months revenue is $55M. |
| What is the current revenue growth of Boule Diagnostics? | Boule Diagnostics revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Boule Diagnostics? | Current revenue multiple of Boule Diagnostics is 0.7x. |
| Is Boule Diagnostics profitable? | Yes, Boule Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boule Diagnostics? | Boule Diagnostics' last 12 months EBITDA is $6M. |
| What is Boule Diagnostics' EBITDA margin? | Boule Diagnostics' last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Boule Diagnostics? | Current EBITDA multiple of Boule Diagnostics is 6.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.